Clinical Trials on Heterozygous Familial

Total 1173 results

University of Pennsylvania

Terminated

[18F]FES PET/CT in PAH

Pulmonary Arterial Hypertension

United States
Bayer

Completed

Study Performed at Various Medical Centers to Learn More About Survival and Expected Course of Pulmonary Arterial Hypertension, a Type of High Blood Pressure in the Lungs Related to the Narrowing of the Small Blood Vessels in the Lungs (START)

Pulmonary Arterial Hypertension

Argentina
United Therapeutics
Lung Biotechnology PBC

Completed

Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH (PRN)

Pulmonary Arterial Hypertension

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...
Mayo Clinic; University of Chicago; Vanderbilt University

Withdrawn

Patient Reported Outcomes in Pulmonary Arterial Hypertension (PROPAH)

Pulmonary Arterial Hypertension
Lundquist Institute for Biomedical Innovation at...
Lung Biotechnology PBC

Completed

Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United States
Pfizer

Completed

Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension
United Therapeutics

Completed

Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, Australia, Hungary, Bulgaria, Czechia, Poland, Romania, Serbia, Spain
Lung Biotechnology PBC

Completed

An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

Pulmonary Arterial Hypertension

United States, Belgium, Ireland
Eli Lilly and Company

Completed

A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, Spain, France, Poland, Canada, United Kingdom
University Medical Center Groningen
Amsterdam UMC, location VUmc

Completed

Ventricular Reversed Remodeling After LTX in PAH Patients (PAH-LTX)

Pulmonary Arterial Hypertension

Netherlands
Akros Pharma Inc.

Withdrawn

Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension (RELIEF-PAH)

Pulmonary Arterial Hypertension
Gilead Sciences

Completed

Selonsertib in Adults With Pulmonary Arterial Hypertension (ARROW)

Pulmonary Arterial Hypertension

Spain, United Kingdom, United States, Netherlands, Germany, Canada, France, Italy
Actelion

Completed

Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument

Pulmonary Arterial Hypertension

United States
Gazi University

Completed

Aerobic Exercise Training in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Turkey
Dokuz Eylul University

Completed

Neuromuscular Electrical Stimulation in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Turkey
Idorsia Pharmaceuticals Ltd.

Terminated

Tezosentan in Patients With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, Japan, France
Massachusetts General Hospital

Completed

Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Hypertension Using Positron Emission Tomography Imaging

Pulmonary Arterial Hypertension

United States
Laval University

Completed

Peripheral Muscle Microcirculation and Exercise-induced Blood Flow Distribution in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Canada
Hospital Universitari Vall d'Hebron Research Institute

Completed

Repeatability of OCT and IV-US in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Spain
United Therapeutics

Withdrawn

Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension
United Therapeutics
CVie Therapeutics Co. Ltd.

Withdrawn

An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

China
United Therapeutics
CVie Therapeutics Co. Ltd.

Withdrawn

Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

China
Dong-A ST Co., Ltd.

Completed

Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)

Pulmonary Arterial Hypertension

Korea, Republic of
The Hospital for Sick Children

Withdrawn

Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children

Pulmonary Arterial Hypertension

Canada
Actelion

Completed

Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) (Compass-2)

Pulmonary Arterial Hypertension

United States, Denmark, Sweden, Germany, Spain, Brazil, Saudi Arabia, Portugal, Greece, Slovakia, United Kingdom, Czech Republic
Eli Lilly and Company

Completed

Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension
Actelion

Completed

Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension (SERAPHIN)

Pulmonary Arterial Hypertension

United States, United Kingdom, Belarus, Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Chile, China, Colombia, Croatia, France, Germany, Hong Kong, Hungary, India, Israel, Italy, Malaysia, Mexico, Netherlands, Norway, Peru, Poland and more
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Austria, Germany, United States, United Kingdom
The Cleveland Clinic

Completed

Coenzyme Q-10 and Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States
Actelion

Completed

Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension (EPITOME-2)

Pulmonary Arterial Hypertension

Spain, Belgium, France, Canada, Italy, Netherlands
Novartis Pharmaceuticals

Terminated

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Switzerland, United States, Germany, Singapore, Korea, Republic of, Canada
University Hospital, Caen

Unknown

Resynchronisation Therapy of Right Ventricle in Pulmonary Arterial Hypertension (RETRIEVE)

Pulmonary Arterial Hypertension

France
Massachusetts General Hospital
Actelion

Withdrawn

Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan

Pulmonary Arterial Hypertension

United States
Gilead Sciences

Terminated

Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

United States, Israel, Australia, Canada, Mexico, Spain, Belgium, Austria, Germany, United Kingdom
United Therapeutics
Asian Clinical Trials

Terminated

Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension (TRUST-1)

Pulmonary Arterial Hypertension

India
Gilead Sciences

Completed

A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)

Pulmonary Arterial Hypertension

Argentina, Brazil, Chile, Mexico
Actelion

Completed

Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401 (EPITOME-1 Ext)

Pulmonary Arterial Hypertension

United States
Lung Biotechnology PBC

Withdrawn

A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor

Pulmonary Arterial Hypertension
Pfizer

Terminated

A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension (STRIDE-3)

Pulmonary Arterial Hypertension

United States, Netherlands, Canada, Belgium, France, Germany, Italy, Spain, United Kingdom, Australia, Poland, Austria, Brazil, Israel, Argentina, Mexico
Medical University of Graz

Completed

The Early Recognition of Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Austria
Leiden University Medical Center
The Dutch Brain Foundation (funding)

Not yet recruiting

Stimulating Amyloid Clearance in Cerebral Amyloid Angiopathy (Clear-Brain)

Cerebral Amyloid Angiopathy
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

X-linked Hypophosphatemia

United States, Korea, Republic of, Japan, Ireland, United Kingdom, France, Italy
Kyowa Kirin Pharmaceutical Development Ltd

Completed

Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH

X-linked Hypophosphatemia

United Kingdom, France, Ireland, Italy
NYU Langone Health

Completed

A Trial of Cognitive Behavioral Therapy in Familial Dysautonomia

Anxiety Disorders | Familial Dysautonomia | Dysthymia | Paroxysmal Hypertension | Autosomal Recessive Disease

United States
Kyowa Hakko Kirin Pharma, Inc.

Completed

A Study of KRN23 in X-linked Hypophosphatemia

X-linked Hypophosphatemia

United States
Vanderbilt University Medical Center
National Institutes of Health (NIH)

Not yet recruiting

Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States
Sheffield Teaching Hospitals NHS Foundation Trust
University of Sheffield; University of Cambridge; University of Newcastle Upon-Tyne and other collaborators

Recruiting

Pulmonary Hypertension: Intensification and Personalisation of Combination Rx (PHoenix)

Pulmonary Arterial Hypertension

United Kingdom
Heinrich-Heine University, Duesseldorf
German Cancer Aid

Not yet recruiting

Prostate Cancer Prevention Clinic for Men With Risk of Familial Prostate Cancer (ProFam-Risk)

Prostate Cancer | Familial Prostate Cancer
Hospital Costa del Sol
Hospital Universitario Virgen Macarena; Hospital San Juan de la Cruz; Hospitales... and other collaborators

Recruiting

RWD Patients With Pulmonary Arterial Hypertension Treated With IP Prostacyclin Receptor Agonists (RAMPHA)

Pulmonary Arterial Hypertension

Spain

Clinical Trials on Heterozygous Familial

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations